-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

How to manage CML patients with comorbidities?

Program: Education Program
Session: Handling Challenging Questions in the Management of CML
Hematology Disease Topics & Pathways:
Diseases, CML, Non-Biological, Therapies, Adverse Events, Myeloid Malignancies, Clinically relevant
Saturday, December 5, 2020, 11:55 AM-12:00 PM

Jorge E. Cortes, MD

Georgia Cancer Center, Augusta University, Augusta, GA

Disclosures: Cortes: Amphivena Therapeutics: Research Funding; Telios: Research Funding; BioPath Holdings: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Arog: Research Funding; Novartis: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Sun Pharma: Research Funding; Merus: Research Funding; BiolineRx: Consultancy, Research Funding; Astellas: Research Funding; Jazz Pharmaceuticals: Consultancy, Research Funding; Bristol-Myers Squibb: Research Funding; Immunogen: Research Funding; Daiichi Sankyo: Consultancy, Research Funding.

OffLabel Disclosure: I may refer to studies on non-approved indications at the time to illustrate some points. If that is the case, I will clearly state those are non-approved indications.

See more of: Handling Challenging Questions in the Management of CML
See more of: Education Program
<< Previous Presentation | Next Presentation